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THE ROLE OF NEUROPILIN 2 IN PHYSIOLOGICAL AND PATHOLOGICAL  
 
ANGIOGENESIS AND LYMPHANGIOGENESIS 
 
 
 
PATRICK MUCKA 
 
ABSTRACT 
 
The generation of new lymphatic vessels through lymphangiogenesis has 
been implicated in many disease states. This process has some overlap with the 
better studied angiogenesis pathway, but is under distinct molecular control. 
Specifically, it has been shown that VEGFR-3 and neuropilin-2 are important 
mediators of lymphangiogenesis. A greater understanding of this process could 
lead to new therapies for cancer and lymphedemas. We investigated lymphatic 
vessel growth in a mouse model with a focus on the effects of neuropilin-2 
knockout. First, we induced an immunogenic response via delayed-type 
hypersensitivity to examine lymphangiogenesis in the physiologic state. Our 
neuropilin-2 knockout mouse model displayed a decreased ability to resolve 
inflammation on exposure to an allergen.  Next, we subcutaneously injected a 
highly invasive melanoma to examine lymphangiogenesis in the pathologic state. 
We noted significantly reduced tumor growth in our neuropilin-2 knockout. In 
addition, the neuropilin-2 knockout mice displayed reduced vessel area in 
comparison to their wild-type littermates, suggesting that inhibition of neuropilin-2 
may prove a potent antitumor therapeutic strategy. These results highlight 
  vii 
neuropilin-2’s important role as a mediator of physiological and pathological 
angiogenesis and lymphangiogenesis.  
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INTRODUCTION 
 
Angiogenesis and Lymphangiogenesis  
 Blood supply is essential for development and growth. During embryonic 
development, vasculogenesis occurs, producing a vascular network from 
precursor angioblasts (Noden, 1989). New vessels are derived from the existing 
vasculature through the endothelial cell (EC) dependent process of 
angiogenesis. During angiogenesis, ECs lining the vessel proliferate and sprout 
toward the region requiring nutrition. This process plays an important role in 
wound healing and immune response and is implicated in a wide variety of 
diseases including cancer, retinopathy and arthritis. Control over this 
phenomenon could lead to potent therapeutic strategies for millions suffering 
worldwide. 
In response to angiogenic signaling, ECs first produce proteases called 
matrix metalloproteinases (MMPs), allowing their dissociation from the basement 
membrane (BM) and passage through it into the stroma. As the ECs move away 
from the existing vessel, one cell is selected as the tip cell. The tip cell continues 
to migrate into the perivascular stroma followed by a stalk of ECs and pericytes 
until another vessel is contacted, when further remodeling produces a nascent 
vessel (Figure 1) (Auerbach & Auerbach, 1994). As blood flow begins through 
the new vessel, nutrient exchange and oxygen perfusion occur, changing the 
microenvironment and removing the stimulus for angiogenic signaling. 
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 Lymphangiogenesis is a parallel process to angiogenesis, referring to the  
generation of new lymphatic vessels from existing ones. While there is still  
Figure 1 │ Angiogenesis: a) Angiogenic signals induce ECs to remodel the 
BM using MMPs, a tip cell is selected. b) Tip cell is guided by more 
angiogenic signals within the stroma, stalk cells follow. ECM is remodeled by 
supporting stalk cells. c) The tip cell meets another vessel, pericytes 
surround nascent vessel and the BM is laid down by ECs lining the new 
vessel. From Carmeliet 2011. 
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debate, evidence shows lymphatic vessels first develop during embryogenesis, 
arising from “lymphatic sacs” themselves derived from embryonic veins (Witte et 
al., 1997). As the blind-ended network of vessels draining the interstitium, 
lymphatic vessels serve to regulate interstitial pressure and provide immune 
surveillance by directing leukocytes to lymph nodes. The involvement of 
lymphatic vessels in many diseases has sparked intense study into the field, 
where research has largely focused on the control of lymphangiogenesis. As 
research has progressed, lymphangiogenesis has become a field distinct from 
angiogenesis under distinct molecular control and with some unique clinical 
implications. 
Modern laboratory techniques have allowed the development of numerous 
models of physiologic and pathologic angiogenesis. However, the most dynamic 
of all models may also be the earliest. Tumors, as rapidly dividing cells, have 
high nutritional demands and their requirement of angiogenesis to supply 
nourishment would serve as the founding observation of this ever-expanding 
field. 
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Cancer 
 In 1971, Dr. Judah Folkman showed that angiogenesis was required for 
tumor growth and metastasis. He theorized that using an inhibitor of 
angiogenesis, or anti-angiogenic compound, could prove a potent therapeutic 
strategy for cancer patients (Folkman, 1971). By illustrating its necessity for 
tumor growth, Folkman had revealed angiogenesis as one of the critical 
processes in cancer cell biology.  
Cancer biology is heavily focused on the key differences that separate our 
normal cells from malignant tumor cells. Research has elucidated several basic 
characteristics defining a malignant tumor cell, which Hanahan and Weinberg 
termed “Hallmarks of Cancer” (Figure 2). These characteristics are acquired by 
non-tumor cells along the path to malignancy. Development of these traits is not 
sequential; cells may acquire different traits at different times.  
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Sufficiency in growth signals normally reserved for cells completing 
programmed replication is characteristic of tumor cells. Tumor cells frequently 
produce their own growth signals, creating a microenvironment conducive to 
growth (Payne & Jones, 2011). Cancer cells also display insensitivity to anti-
growth signals that would typically shut down growth due to contact inhibition or 
activation of tumor suppressor genes. In conjunction with these two signaling 
modifications, cancer cells frequently achieve unlimited replicative potential 
through up-regulation of telomerase activity (Blasco, 2002). Although cells have 
natural apoptotic mechanisms to defeat such replication, tumor cells circumvent 
these pathways. Pro-apoptotic signaling pathway molecules p53, cytochrome C 
Figure 2 │Tumor Characteristics: Characteristics that tumor cells acquire 
on the way to malignancy. The tumor shown in the center reflects the theory 
of heterozygous tumor composition. From Hanahan and Weinberg 2001. 
 6 
and caspase-8 have all been shown as deregulated in many cancers (Derksen et 
al., 2006; Hanahan and Weinberg, 2000). The ability to initiate angiogenesis has 
been confirmed as a defining feature of a malignant tumor cell (Hanahan and 
Weinberg, 2011). Angiogenesis was also shown to be required for metastasis. 
During growth, nearly all tumor cells metastasize from their primary site to distant 
locations throughout the body, the resultant growth of which cause 90% of all 
cancer deaths (Sporn, 1996). In theory, by creating an anti-angiogenic therapy, 
not only could growth be stopped but lethal metastasis prevented, giving 
antiangiogenic therapies great clinical relevance.  
Current evidence supports a tumor composition that is heterogeneous, 
containing a variety tumor cells and additional stromal cells contributing to the 
tumor microenvironment (Hanahan and Weinberg, 2011; Naumov et al. 2006). 
Such coordination within the tumor produces an environment where single cells 
need not acquire all characteristics necessary for invasion and malignancy, they 
can benefit from the progression of other cells by being exposed to the enriched 
tumor microenvironment (Fidler, 2003).  
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Metastasis 
 Metastasis is the spread of tumor cells from the primary growth to a 
distant, or secondary, growth site (Naumov et al., 2006). Much like angiogenesis, 
metastasis is a complex sequential process reliant largely on the ability of 
migrating cells to traverse the various cellular barriers (Figure 3). Metastasis 
begins when tumor cells have acquired several of the previously discussed 
characteristics and have created a supportive tumor microenvironment (Egeblad 
et al., 2010). These cells recruit new vessels through angiogenesis, creating a 
route away from the tumor in addition to bringing nutrition in. The tumor cells 
express adhesion molecules such as modified laminin receptors to attach to the 
BM of the new vessels (Barsky et al, 1984a). Elements of the ECM and BM such 
as collagen pose a significant obstacle to migrating invasive cells. Tumor cells 
are able to pass through the basement membrane using MMPs and other 
proteases, which are frequently overexpressed in tumors (Mueller & Fusenig, 
2004). Once in the vessel, the tumor cell is able to metastasize to a distant site 
under the direction of additional chemokines (Fidler 2002). Upon arrival, tumor 
cells adhere to the vessel wall and begin the process of extravasation in a similar 
fashion to the prior vessel intravasation. Tumor establishment and growth at the 
new site is dependent on the presence of a supportive microenvironment. If the 
tumor cells survive and are able to recruit new vessels, growth occurs, beginning 
the metastatic cycle again. The selective pressure exerted by the multiple 
barriers in metastasis assure that only the most invasive cells are able to 
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successfully become established tumor growths, resulting in a secondary tumor 
that is far more malignant than its primary.  
 
 
 
 
 
 
 
Examination of tumor models of angiogenesis has yielded important 
insight in the variable nature of vessel formation. Tumor vessels are disorganized 
Figure 3 │ Metastatic Sequence: The primary tumor (top left) recruits vessels 
through angiogenesis. Tumor cells (in blue) enter the circulation through 
capillaries, venules and lymphatic vessels (top right), travel through the 
circulation and adhere to the vessel wall at a distant site (center left). Tumor 
cells extravasate into the stroma, where their success in forming a new tumor 
depends on the microenvironment (bottom center). If the microenvironment is 
supportive of growth, the metastatic cycle begins again (bottom right). From  
Fidler 2010. 
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and have discontinuous basement membranes, causing them to be leaky (Nagy 
and Dvorak, 2012; Hashizume et al., 2000). Lacking the integrity of a normal BM 
and pericyte sheath, these vessels are easy targets for invasive cells (Liotta et 
al., 1991). Normalization of tumor vasculature occurs with the application of 
some antiangiogenic compounds, indicating that it may be possible to confound 
the invasive abilities of tumor cells through such therapy (Jain, 2005). 
 Lymphatics normally form discontinuous BMs with large interendothelial 
gaps without a pericyte sheath, making the vessels easier to penetrate than 
normal blood vessels (Sauter et al., 1998; Zwaans & Bielenberg, 2007). Thus, 
from a structural point of view, lymphatics represent less of a challenge to 
metastasis as tumor blood vessels. Once in the lymph, the tumor cell faces a far 
less harsh environment than found within the blood circulation enabling greater 
survivability and proliferation for the cell. In the clinic, carcinomas have been 
shown to preferentially metastasize through lymphatic vessels (Pepper, 2001). 
As such, finding a way to inhibit lymphangiogenesis may represent a viable 
therapeutic strategy alongside antiangiogenic therapies. 
 The cost of pathological angiogenesis to the host and the conceptual 
understanding of possible therapeutic intervention now apparent, the question of 
control over angiogenesis remains. The true players in angiogenesis stayed 
unknown for many years, but this did not prevent key investigators from 
formulating a theoretical framework for the elements to function within. 
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Control of Angiogenesis 
In addition to his other findings in 1971, Judah Folkman was able to 
isolate a molecule he termed tumor angiogenic factor (TAF) (Folkman, 1971). 
This molecule was the first isolated molecule that could be termed pro-
angiogenic; it had the ability to repeatedly induce physiologic angiogenesis and 
to activate tumors from dormancy, leading to pathologic angiogenesis. The 
hypothesis of an “angiogenic switch” or scale with angiogenic molecules on one 
side, antiangiogenic molecules on the other, began gaining traction within the 
field (Figure 4). By adding molecules to the angiogenic side, the scale can be 
tipped to favor angiogenesis and vice versa. The hypothesis proposed that 
normal cells contain a balance of pro/antiangiogenic molecules. During normal 
physiologic function, the cell can modify its microenvironment and that of 
neighboring cells, signaling for angiogenesis in response to hypoxia or immune 
reaction. When the needs of the cell are met, the microenvironment shifts back 
towards a balanced composition. When applied to tumor microenvironments, the 
hypothesis predicted an abundance of angiogenic molecules would be found 
driving the pathologic angiogenesis (Liotta et al., 1991). 
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 With the advent of molecular techniques in the 1980’s, many angiogenic 
molecules were finally characterized. Basic fibroblast growth factor (bFGF), 
acidic fibroblast growth factor (aFGF), platelet derived growth factor (PDGF), 
interleukin-1β (IL-1β), hypoxic inducible factor-1α/β (HIF-1α, HIF-1β) and 
vascular endothelial growth factor (VEGF) are a few of the key angiogenic 
molecules. These molecules function largely by acting as ligands, signaling 
through an equally diverse array of receptor tyrosine kinases (Carmeliet, 2000). 
To balance out such factors, there are also numerous endogenous 
antiangiogenic molecules such as thrombospondin-1 (TSP-1), α and β interferon, 
Figure 4 │ Angiogenic Switch:  The angiogenic switch, with angiogenic 
molecules in blue and antiangiogenic molecules in red. When angiogenic 
molecules “outweigh” antiangiogenic molecules, the switch is considered “on” 
and angiogenesis proceeds. From Hanahan and Folkman 1996. 
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semaphorin 3 and platelet factor-4. Many of these molecules have several 
isoforms allowing additional modulation to the angiogenic cascade, indicating 
that the “switch” may really be more like “scale”, with a wide range of responses 
depending not only on the “weight” but also the composition of each “load”. 
 The wide range of signaling options available allow the body to respond to 
many different physiologic and pathologic instigators of angiogenesis and 
lymphangiogenesis. Physiologic angiogenesis is most frequently driven by 
hypoxia. The 200µm diffusion limit of oxygen represents the maximum distance a 
cell can be placed from a capillary without hypoxic effects (Filho et al., 1994). 
Physiologic angiogenesis also occurs during some immune reactions to aid in 
leukocyte delivery to and interstitial drainage from the affected site. Pathologic 
angiogenesis can also be driven directly by hypoxia, but aberrant signaling is 
usually the main motivating force. Tumors are the most obvious example of 
signaling gone awry. When initiating growth, angiogenesis is likely triggered by 
hypoxia within the tumor (Filho et al., 1994). However, as the tumor grows and 
the cells acquire more invasive characteristics, some tumors may begin to 
overexpress various angiogenic molecules enriching the microenvironment. This 
leads to greater tumor vascularization, more growth and a further enriched tumor 
microenvironment. Thus, to bring angiogenesis back into balance within the 
tumor, angiogenic molecules must be removed or antiangiogenic molecules 
added. Because of its wide diversity of roles in angiogenic signaling, the VEGF 
family has been the focus of most therapeutic strategies to date. 
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VEGF and Receptors 
 Vascular endothelial growth factor (VEGF) was first described as a 
modulator of vascular permeability but has since been described as a powerful 
inducer of EC proliferation, migration and production of proteases. The VEGF 
family is comprised of five genes, VEGFA, VEGFB, VEGFC, VEGFD and VEGFE 
all coding for proteins that function as ~40kDa dimers (Ferrara, 1996). In 
addition, VEGFA undergoes mRNA processing to produce four separate 
isoforms VEGF121, VEGF165, VEGF189, VEGF206, of which VEGF165 is the most 
abundant in both physiologic and pathologic condition. VEGF165 contains a 
heparin-binding domain that aids in extracellular matrix binding, keeping this 
isoform local when secreted, as opposed to VEGFA121 which lacks this domain 
and is freely soluble to disperse (Klagsbrun & D’Amore, 1996). The VEGFs 
belong to the cysteine knot growth factor family and all contain a ~100 amino 
acid homology domain containing 8 cysteine residues used for binding to 
receptors. 
 The VEGFs bind two separate families of receptors the VEGFR family of 
tyrosine kinase receptors and the neuropilin family (NRP1 and NRP2). The 
VEGFR family consists of three receptors VEGFR1, VEGFR2 and VEGFR3. The 
VEGFRs contain 7 extracellular immunoglobulin domains and have cytosolic 
tyrosine kinase domains (Ferrara et al., 2003). The receptors signal through 
normal tyrosine kinase behavior and have differential affinities for the VEGFs 
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(Figure 5). VEGFR1 binds VEGFA, VEGFB and PIGF and is expressed on 
macrophages, monocytes and ECs. VEGFR2 binds VEGFA, VEGFC, VEGFD 
and VEGFE and is expressed on ECs, hematopoietic cells, neuronal cells and 
some tumor cells (Roskoski, 2007). VEGFA binds VEGFR1 with 10 times the 
affinity it binds VEGFR2. However, this difference in affinity is compensated by 
the reduced amount of autophosphorylation by VEGFR1 when compared to 
VEGFR2 (Seetharam et al., 1995). The greater tyrosine kinase activity seen by 
VEGFR2 has led to its acceptance as the major regulator of VEGF-induced cell 
proliferation, migration and angiogenesis (Ferrara et al., 2003). The signal is 
primarily transduced by the PLCγ-PKC-Raf-MEK-MAPK pathway which initiates 
DNA synthesis in ECs, preparing the cells for mitosis (Shibuya & Claesson-
Welsh, 2006). Of course as an instigator of angiogenesis, VEGFR2 also signals 
for cell migration, achieved using the Shb-PI3K pathway initiating actin 
organization and cell migration (Roskoski, 2007). Due to its potent signaling 
capabilities, VEGFR2 has been the primary target of antiangiogenic therapies. 
Finally, VEGFR3 binds only VEGFC and VEGFD and is found on vascular ECs 
during development. Studies in transgenic VEGFR3 knockout mice are 
embryonic lethal around E11, indicating a critical role for VEGFR3 in the 
developing vasculature (Dumont et al., 1998). In the adult organism VEGFR3 is 
expressed only in the ECs lining the lymphatic vasculature, making this receptor 
the focus of much study within the lymphangiogenesis field. 
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Figure 5 │ VEGF and VEGF Receptors:  Ligands of the VEGFRs are 
shown with indications of their binding preferences (Top). The VEGFRs 
(middle) contain six or seven immunoglobulin binding domains used to 
bind the ligands shown above. A short transmembrane area links to the 
intracellular kinase domains used to signal downstream pathways. 
Adapted from Ruiz de Almodovar et al. 2009 
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Neuropilin Receptors 
 The second family of receptors bound by the VEGFs is the neuropilins 
(NRPs), NRP1, NRP2 and soluble NRP. NRPs were originally discovered as 
receptors for semaphorins, playing a role in neuronal growth and guidance 
(Takagi et al., 1991). In 1998, NRP was shown to bind VEGF also, implicating 
the receptor as a regulator of angiogenesis (Soker et al., 1998). The NRP family 
receptors are both ~135kDa with ~44% amino acid homology (Giger et al., 1998). 
The structure contains a large extracellular domain divided into several 
subdomains, a transmembrane domain, and an intracellular domain. The 
extracellular domain contains two complement binding domains termed a1 and 
a2, two coagulation factor V/VII termed b1 and b2, and a meprin domain (MAM) 
designated c (Chen et al., 1997).  
The c and transmembrane domains play a significant role in dimerization, 
which is an essential aspect of neuropilin signaling (Geretti et al, 2008). The 
b1/b2 domains contain heparin binding domains (HBD) and are necessary for 
receptor-ligand interaction for both VEGF and semaphorin-3s (Mamluk et al., 
2002). The b1/b2 domains contain binding sites for VEGFs, which is mediated 
through interactions with amino acids corresponding to exon 7, as opposed to 
VEGFR-VEGF binding interactions with the conserved cysteine knot motif (Soker 
et al, 1996; Weismann et al., 1997). NRP1 and NRP2 have differing specificities 
for the VEGFs, with NRP1 binds VEGFA, VEGFB, VEGFE and PIGF2 while 
NRP2 binds VEGFA, VEGFC, VEGFD and PIGF2 (Klagsbrun et al., 2002; Gaur 
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et al., 2009). Signaling is achieved through association with VEGFRs also 
present in the membrane, with VEGF acting as a “bridge” between the two 
receptors. Both NRPs associate with VEGFR2, mediated by VEGFA, to enhance 
angiogenic signaling. NRP2 also associates with VEGFR3, mediated by VEGFC, 
to enhance lymphangiogenic signaling (Favier et al., 2006).  
The a1/a2 domains on NRP contain binding sites for class 3 semaphorins 
(SEMA3s), which also require the b1/2 domain to bind NRP. The SEMA3s were 
the first NRP ligand discovered (Kolodkin et al., 1997). These molecules produce 
a collapsing cell phenotype produced by actin cytoskeleton depolymerization, 
leading to inhibition of migration (Sakurai et al., 2012; Bielenberg et al. 2008). 
SEMA3 signaling through NRP is achieved through dimerization with an 
additional receptor from the plexin family (Puschel, 2002). Plexins are capable of 
activating many intracellular signaling pathways including those that control 
cytoskeleton dynamics and proliferation such as Rho and Ras, as well as kinases 
like SRC, PI3K and MAPK (Gaur et al., 2009). 
NRP’s modulation of VEGFR signaling presents it as an ideal target for 
antiangiogenic therapy and the activity of SEMA3s to inhibit VEGF-NRP binding 
reinforces this, suggesting that SEMA3s may make an excellent therapeutic 
agent. Investigation of NRP expression and function in murine models has 
proved essential for the study of this family of receptors. 
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Neuropilin Transgenic Mice 
 In 1997, NRP1 overexpression was shown to produce an embryonic lethal 
phenotype by Kitsukawa. Abnormalities were found in NRP-expressing organs 
within the developing nervous system, cardiovascular system and limbs. 
Embryos overexpressing NRP displayed excess vessels, dilation of vessels and 
an abnormal heart. The study determined that the cardiovascular abnormalities 
were the likely cause of lethality in the embryos indicating NRP1 is essential in 
the development of the nervous system (Kitsukawa et al., 1997). Further studies 
in a NRP1 knockout mouse produced similar embryonic lethality at around day 
E13. These also embryos show greatly disorganized vasculature which 
suggested that the phenotype was due to disruption of NRP1-VEGFR2 
association (Kawasaki et al., 1999). Mice null for both NRPs are embryonic lethal 
at ~E8.5 with even more vascular disorganization and additional hemorrhaging, 
similar to a VEGFR2 knockout (Takashima et al. 2002).  
 NRP2 knockout mice are not embryonic lethal and display a loss of 
lymphatic capillary and small vessel formation during development while all other 
vessels including arteries, veins and large lymphatic vessels developed normally 
(Yuan et al., 2002 )(Figure 6). This phenotype corresponded with a reduction in 
DNA synthesis in lymphatic endothelial cells (LECs), indicating that these cells 
were not proliferating in the mutants. A similar phenotype was more recently 
described in double heterozygote NRP2/VEGFR3 mice which were unable to 
sprout lymphatic vessels in response to VEGFC, further implicating NRP2 as an 
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important mediator of lymphangiogenesis (Xu et al, 2010). Reinforcing this idea, 
a reduction of VEGFC mediated tumor lymphangiogenesis and metastasis was 
shown after treatment of mice with an anti-NRP2 antibody (Caunt et al., 2008). 
 
 
 
  
 
In our laboratory, we have Nrp2gfp/gfp (NRP2 KO) and Lyve/Cre mice. The 
Nrp2 KO mice have a GFP gene knocked in at the location of the Nrp2 gene 
while the Nrp2 gene is knocked out. These mice do not have a different 
phenotype than normal Nrp2 knockout mice other than the presence of GFP in 
Nrp2 expressing tissues, allowing for quick genotyping of wild-type mice. The 
Lyve/Cre mice contain a Cre gene following a wild-type Lyve-1 promoter. Lyve-1 
is a lymphatic marker first identified as a hyaluronan receptor (Jackson et al., 
2001). Cre is a tyrosine recombinase derived from the P1 bacteriophage which is 
Figure 6 │Compromised Lymphatic Development in VEGFR3 
Knockouts: Brown staining is for VEGFR3, a lymphatic marker. Along the 
top, a VEGFR3 mutant mouse with one allele knocked out is shown to have 
lymphatic vessels. Below, a mutant mouse with both alleles of VEGFR3 
knocked out shows compromised development of small lymphatic vessels. 
From Yuan et al. 2002 
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able to carry out site-specific recombination. The Cre enzyme recognizes the 
presence and orientation of loxP sites found within the DNA. Genes bookended 
by loxP are termed “floxed” as are the mice hosting them e.g. floxed Nrp2 mice. 
By breeding a Lyve/Cre mouse with a floxed Nrp2 mouse, a tissue specific 
knockout is produced in the offspring, which do not express Nrp2 in lymphatic 
vessels. This knockout is essential to the deeper investigation of the role NRP2 
plays in lymphangiogenesis because it allows us to explore the role of NRP2 
expression on lymphatics alone. Such study is required due to the broad and 
varied expression of NRPs within the body. 
 
Physiologic Neuropilin Expression 
 Neuropilins are expressed in a continually expanding variety of organs 
and cell types further implicating them in additional roles far beyond their initial 
neuronal guidance role and the angiogenesis mediation investigated in this thesis 
(Wild et al., 2012). NRP1 and NRP2 are expressed differentially in the epithelia 
of various organs, but expression is not mutually exclusive. A study of NRP1 
indicated its expression in the epithelia of breast, lung and blood vessels 
(Gagnon et al., 2000). Previous studies by our group have shown NRP2 
expression in uterus, skin, lung, intestine and brain whole organ lysates (Figure 
7). During development, NRP1 and NRP2 are expressed differentially in arterial 
and venous ECs respectively (Herzog et al., 2001). In the mature organism 
expression is not as clearly defined with ECs in blood, vein and lymphatic 
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vessels all variably expressing NRP2 (Bielenberg et al., 2006). Previous work by 
Nick Levonyak in the lab has shown variable expression in the central lacteal of 
intestinal villi, as well as lung ECs, providing further evidence for this NRP2’s 
heterogenous expression. Immunohistochemical staining also revealed high 
expression of NRP2 in cutaneous vessels during the same study. Due to this 
finding, it was hypothesized that both wound healing and resolution of allergen-
induced inflammation (two important physiologic angiogenesis processes) would 
be compromised. Interestingly, Levonyak found that wound healing was not 
compromised in NRP2 knockout mice, suggesting that it may be possible to 
compensate through another pathway. In addition, NRP2 expression on LECs is 
completely exclusive of NRP1 expression giving further precedent for the 
lymphatic phenotype found in NRP2 KO mice (Yuan et al., 2002; Bielenberg et 
al., 2004). 
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NRPs are not limited to guidance and migration roles. Currently, the role 
of NRP in immune response is also being heavily investigated since NRPs are 
expressed on leukocytes as well as macrophages and dendritic cells (DCs) 
(Stepanova et al., 2007; de Paulis et al., 2006). NRP1 has been shown to 
mediate the interaction between DCs and T-cells and inhibition of this interaction 
was shown to prevent DC-mediated proliferation of T-cells (Tordjman et al., 
2002). Roles like this one are still being discovered for NRPs, implicating them in 
inflammation, a field which is rapidly converging with the study of cancer. NRPs 
may also be excellent targets for transplant immunity therapies. Knockdown of 
NRP2 by shRNA has shown enhanced the survival of corneal allografts by 
inhibiting local lymphangiogenesis (Tang et al., 2010). The expanding role of 
Figure 7 │ NRP2 expression measured by western blot: NRP2 protein 
levels in various tissues were measured by western blot using whole organ 
lysates. Also present is a band around 85kDa, representing sNRP. GAPDH 
expression was measured to check loading equivalence of samples. From 
Nick Levonyak, 2013 
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NRP in the immune response along with the growing number of normal cells 
shown to express NRPs increasingly implicates them in physiologic functioning. 
 
Pathologic Neuropilin Expression 
 Neuropilins are found in a wide variety of tumor types. Their expression is 
not mutually exclusive, but one is typically predominant if both are present. NRP1 
expression is found in greater levels in carcinomas, while NRP2 is more heavily 
expressed in melanomas, glioblastomas and neuroblastomas. Thus, NRP2 is 
found more often in tumors originating for neural crest cells, although there are 
notable exceptions such as pancreatic ductal adenocarcinoma, which highly 
expresses NRP2 (Bielenberg et al., 2006; Fukahi et al., 2004).  
NRP expression was first reported in PC3 prostate and MDA-MD-231 
breast cancer cell lines (Soker et al., 1998). Further studies have shown NRP 
expression in bladder, colon, pancreas, kidney, ovarian, skin and lung 
carcinomas (Wey et al., 2004; Neufeld et al., 2005). Interestingly, some of these 
tissues normally do not express NRPs or do not express NRP1 or NRP2 while 
expressing the other. The former was shown in three pancreatic cancer cell lines, 
which expressed high levels of NRP1 and NRP2. Normally, pancreatic cells are 
completely devoid NRP1 and lowly express NRP2 (Fukahi et al., 2004). 
Malignant prostate carcinoma samples showed a ten-fold increase in NRP1 over 
their normally very low levels, with higher levels of NRP1 correlating with more 
invasive phenotypes (Vanveldhuizen et al., 2003). 
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 Histological analysis of prostate tumors overexpressing Nrp1 in rats 
showed increased vessel density and proliferation, along with high levels of 
VEGF, indicating that angiogenesis occurred (Miao et al., 2000). These tumors 
were shown to be VEGFR negative, removing the possibility of autocrine 
signaling as the cause of the increased tumor growth. Even without direct 
signaling, VEGF may still have initiated angiogenesis by creating a gradient in 
which the tumor microenvironment was more supportive of angiogenesis than the 
surrounding tissue, thus attracting sprouting vessels. In a theory termed the 
“VEGF sequestration” hypothesis, NRP1 was proposed as a reservoir for VEGF, 
keeping the concentration in the tumor higher than would be possible with free 
VEGF. It is possible that NRP2 also functions in this manner with VEGFA, 
VEGFC and VEGFD. More recently, NRP2 knockdown via shRNA produced 
tumor cells which displayed markedly impaired migration, invasion and growth 
capabilities (Dallas et al., 2008). In addition, tumor size was reduced by as much 
as 95% in the tumors. Considered together, these findings show that inhibition of 
NRP2 inhibits tumorigenicity and progression through direct action on NRP2-
expressing tumor cell as well as tumor growth and angiogenesis by the direct 
effects on NRP2-expressing vessels. 
Cancer is not the only pathology of consequence for our group; lymphatic 
malformation (LM), also known as lymphangioma, represents an area that has 
received relatively little study, yet has the prospect of profound clinical impact. 
LMs consist of masses of abnormal lymphatic vessels that continually proliferate, 
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ultimately forming an edematous mass. These vascular anomalies commonly 
occur in the head and neck reason, which can drastically affect function of the 
respiratory and digestive tract. In addition, they are commonly visible to naked 
eye and can be disfiguring, which has a negative impact on patient outlook 
(Figure 8). Currently, the only treatments available are surgical options to remove 
the LM, which do nothing to prevent the anomaly from coming back (Perkins & 
Manning, 2010). In addition, there is no animal model for this disorder, which has 
led to a clinical focus in the field. The development of a model would allow the 
underlying mechanisms driving LMs to be studied and is consequently the focus 
of many already working in the vascular biology field. Our current understanding 
of NRP as a mediator of lymphangiogenesis suggests that it may be possible to 
use an antilymphangiogenic compound, such as SEMA3F, to suppress the 
growth of LMs. 
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Class 3 Semaphorins 
 Class 3 Semaphorins (SEMA3s) were first discovered as axonal guidance 
molecules, but their role has been expanded to include action in angiogenesis as 
well. There are 7 SEMA3s (SEMA3A-G), which are structurally composed of an 
N-terminal SEMA domain, a plexin-semaphorin-integrin (PSI) domain, an Ig loop 
and a C-terminal basic domain. They also contain several endoprotease 
cleavage sites that play roles in regulating the activity of SEMA3s. The SEMA 
Figure 8 │Lymphatic malformation in a patient:  As seen here, lymphatic 
malformations are characterized by red, edematous swellings that commonly 
occur in the head and neck. As the malformation grows, it can become “hot” 
due to extensive, but dysfunctional vascularization and painful, due to the 
increased interstitial pressure from dysfunctional drainage. From Perkins and 
Manning 2012. 
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domain contains a 7-bladed β propeller motif that is used for NRP binding 
(Gherardi et al, 2004). The C-terminal domain has been proven to be essential 
for SEMA3 dimerization (Klostermann et al., 1998). Most SEMA3s bind NRP2, 
with the notable exception SEMA3A, which requires NRP1 for signaling (Figure 
9) (Chen et al, 1997).  
Several theories exist as to SEMA3’s mechanism of action, but most 
recent evidence supports their depolymerization of F-actin filaments as the cause 
of their inhibitory action (Shimizu et al. 2008). This result was confirmed by Matt 
Migliozzi in the lab in porcine aortic epithelial cells overexpressing NRP2. This 
mechanism of action causes the cytoskeleton to lose shape, preventing ECs 
from extending processes needed for motility. Others have suggested that these 
effects are due to the inhibition of VEGF-NRP interaction or inactivation of 
integrins on ECs, disrupting angiogenesis (Guttmann-Raviv et al. 2007; Serini et 
al., 2003). The SEMA3s act as competitive inhibitors of the VEGFs, with higher 
concentrations of SEMA3A shown to be necessary to produce growth cone 
collapse in the presence of VEGFA (Miao et al., 1999).  
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SEMA3A and SEMA3F are capable of inhibiting EC proliferation and 
migration, making them promising as antiangiogenic therapeutics. Tumors 
overexpressing SEMA3A have decreased vascularization and metastatic 
potential (Bachelder et al., 2003; Moretti et al., 2008; Vacca et al, 2006). 
Previous work by our group and others has shown that many of these effects are 
recapitulated with SEMA3F (Bielenberg et al., 2004; Kessler et al., 2004). In 
addition, Matt Migliozzi from the lab has shown that SEMA3F is effective in 
reducing tumor vascularization in vivo. Critically, he found that there was a 
reduction in the lymphatics surrounding the tumor, indicating that SEMA3F may 
be able to confound tumor cell access to lymphatic vessels and thus their ability 
Figure 9 │SEMA3-NRP-Plexin Interaction:  Class 3 semaphorins are shown 
(red diamond) with binding preferences for the NRPs (green). The SEMA-
NRP complex is shown associated with the transmembrane plexin receptor 
(blue), which uses kinase (domains in purple) activity to activate downstream 
targets. Adapted from Gaur et al., 2009 
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to metastasize in vivo. Loss of expression of SEMA3s has been correlated with 
advanced stage lung cancers and melanomas, indicating that their therapeutic 
replacement may be a viable treatment option in vivo (Bielenberg et al, 2004; 
Lantuejoul et al., 2003). Taken together, these findings suggest that SEMA3F 
may be an effective antitumor and antimetastatic therapeutic. 
 
In vivo Assays 
 Many assays have been designed to study angiogenesis in both 
physiologic and pathologic conditions. Physiologic assays, like physiologic 
angiogenesis, are more frequently driven by hypoxia or immune response as in 
wound healing and allergic reaction. On the other hand pathologic assays, such 
as tumor growth assays, reflect aberrant signaling (i.e. VEGFC overexpression in 
our B16F10 line) not seen in physiologic conditions. In this study, we made use 
of one physiologic assay, the delayed-type hypersensitivity assay and one 
pathologic assay, the tumor growth assay. 
 Delayed-type hypersensitivity (DTH) reactions are type IV hypersensitivity 
reactions and are so named because the response to allergen exposure is not 
immediate, requiring hours to days to reach full effect. This is in stark contrast to 
immediate hypersensitivity reactions in which the full response occurs in seconds 
to minutes. Type IV hypersensitivity reactions are unique among the 
hypersensitivities in that they are completely cell-mediated and do not involve an 
antibody response (Uzzaman & Cho, 2012). 
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 As a cell-mediated response, the key players in DTH are macrophages 
and leukocytes, which are NRP2 expressing cells. Initial exposure to an allergen 
causes macrophages to phagocytize the molecule and present it to Th-1 cells on 
a class II major histocompatibility complex (MHC). Th-1 cells are activated by this 
interaction, causing proliferation, in essence “priming” the system for a second 
exposure. On second exposure to the allergen, Th-1 cells recognize the allergen 
and secrete interferon-γ (IFN-γ), which is a potent stimulator of macrophages. 
Once at the exposure site, macrophages secrete tumor necrosis factor α (TNF-α) 
and interleukin-1 (IL-1) both of which are inflammatory and recruit additional 
macrophages leading to further inflammation. As the concentration of allergen 
decreases, less macrophages are recruited until finally the inflammatory 
response is resolved (Czarnobliska et al., 2007) 
 Of course, for this inflammation to be resolved the leukocytes and 
macrophages must first reach the site of exposure. Macrophages local to the 
exposure are the first to respond, yet others must extravasate to reach the 
allergen. During DTH reactions, vascular remodeling occurs, allowing responding 
immune cells to be deposited closer to the site of exposure. Studies in VEGFA 
overexpressing transgenic mice have shown prolonged inflammatory response 
and enlarged lymphatics using the same DTH assay used in this study (Kunstfeld 
et al, 2004). When VEGFA signaling was blocked through systemic application of 
VEGFR1 and VEGFR2 antibodies, inflammation did not occur, suggesting that 
being able to turn the angiogenic switch on and off is important in normal 
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physiologic functioning. This assay allowed us to examine the role NRP2 plays in 
physiologic angiogenesis, which has not been previously described. 
 The second in vivo assay used in this study is a tumor growth study using 
mouse B16 melanoma. We studied angiogenesis in cancer for the reasons 
discussed above, but there are two additional reasons our group used B16 
melanoma for this study. B16 is one of the few murine cancer models that are 
NRP2 positive, as was previously confirmed by Meetu Seth in our lab. This 
finding is crucial for our study of NRP2’s role in tumor angiogenesis. Melanomas 
preferentially use Nrp2-positive lymphatics to metastasize, thus an exploration of 
Nrp’s role in this could reveal why degree of lymphangiogenesis correlates with 
poor outcome in the clinic. In addition, there is no shortage of evidence 
supporting melanoma as the most lethal skin cancer.. By further investigating this 
highly invasive melanoma, we hope to determine if SEMA3F could be an 
effective antitumor and antimetastatic agent for this deadly form of cancer. 
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METHODS 
 
Cell Culture 
 
General Cell Culture 
 B16F10 melanoma cells, B16F10 melanoma cells transfected with 
VEGFC, A375SM melanoma cells, porcine aortic endothelial (PAE) cells 
transfected with either neuropilin1 (PAEnrp1) or neuropilin2 (PAEnrp2) and 
human umbilical vein endothelial (HUVEC) cells were removed from storage in 
liquid nitrogen and rapidly thawed in 37°C water bath. The cells were cultured in 
100mm plates with 10mL of complete media with appropriate media (Table 1). 
Media was made complete by supplementing the appropriate media with 10% 
Fetal Bovine Serum (FBS) and 1% glutamine-penicillin-streptomycin (GPS). Cells 
were cultured in humidified 37°C incubators at either 5% or 10% CO2 (Table 1). 
After 24 hours, the media was aspirated and replaced with 10mL of appropriate 
media. Media was aspirated and replaced with fresh every 4 days until plates 
were visually fully confluent. 
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Cell Line Media CO2 % 
A375SM Clean MEM 10 
B16F10 DMEM 5 
B16F10 VEGFC DMEM 5 
HUVEC EGM2  5 
LM EGM2-MV 5 or 10 
PAE Nrp1 Ham's F12 Modified 5 
PAE Nrp2 Ham's F12 Modified 5 
 
 
 Once confluent, media was aspirated and plates were washed with 3mL 
0.05% Trypsin ethylenediaminetetraacetic acid (EDTA) followed by an additional 
1mL Trypsin-EDTA(Gibco). Plates were incubated at 37°C in humidified 
incubators for 5 to 10 minutes to allow cells to trypsinize and lift off plates. 
Trypsin-EDTA was then inactivated using either media or trypsin neutralizing 
solution (TNS)(Gibco). If TNS was used, cells were centrifuged at 1000rpm for 5 
minutes and resuspended in appropriate media. Cells were added to new 
100mm plates with 10mL fresh media. 
 Cells were frozen down as stock for later use by first trypsinizing cells, 
then resuspending them in freezing media composed of 70% appropriate media 
(Table 1), 20% (FBS) and 10% Dimethylsulfoxide (DMSO). Cells were pipetted 
into cryogenic vials and placed in a Mr.Frosty insulated with 250mL isopropanol. 
Table 1 │ Cell Culture Information: Cell lines were 
cultured in corresponding media. All cells were placed in 
humidified 37°C incubators with the listed 5% or 10% CO2. 
 34 
Tubes were frozen overnight to -80°C and then placed in liquid nitrogen for 
storage. 
 
Protein Isolation 
 Once visually confluent, cells were placed on ice and washed with 
phosphate buffered saline twice (PBS). Protein Lysis Buffer was prepared by 
dissolving one ULTRA mini tablet protease inhibitor in 10ml radio immune 
precipitation assay buffer (RIPA)(Roche). PBS was removed and 500µL of Lysis 
Buffer was added. Plates were scraped, ultimately sweeping lysis product to one 
side of the plate. Liquid was transferred to small tube and allowed to sit on ice for 
20 minutes. The tube was then centrifuged at 14,000rpm for 10 minutes to pellet 
cell bodies, after which the supernatant was removed and frozen as cell lysate 
and the pellet discarded. 
  
 
Protein Analysis 
 
Protein Assay 
 Cell lysates were assayed to determine total protein concentration using a 
Bio-Rad DC Protein Assay. A standard was prepared in a 96 well plate by serially 
diluting BSA and pipetting 5µL aliquots in triplicate. 5µL samples were added in 
duplicate to the plate. 20µL Protein Assay Solution S (Bio-Rad) was added to 
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1mL of Protein Assay Solution A (Bio-Rad) to yield a 2% A+S solution. 25µL of 
A+S solution was added to each well except those used to serially dilute the BSA 
standard. 200µL Protein Assay Solution S (Bio-Rad) the same wells as A+S 
solution. The plate was allowed to incubate at room temperature for 5 minutes 
before being read by a VERSAmax microplate reader (Molecular Devices) at 
750nm. The standard readings were uses to produce a graph in Microsoft Excel. 
The best-fit line formula was used to calculate the protein concentrations of each 
sample. 
 
Casting an SDS-Page Gel for Western Blot 
 The resolving layer solution was made with 3.75mL of 30% 
acrylamide/0.8% bis-acrylamide (National Diagnostics), 3.75mL of 4x 1.5M tris-
HCl/0.4% SDS pH 8.8 (National Diagnostics), 7.5mL sterilized distilled water, 
50µL of 10% ammonium persulfate (APS), and 10µL 
tetramethylethylethylenediamine (TEMED). This solution was pipetted into a gel 
mold (Bio-Rad) and topped with a thin layer of methanol to produce a flat surface 
for the stacking layer. The cast was allowed to incubate at room temperature for 
approximately 30 minutes to allow the resolving layer to polymerize. The 
methanol layer was discarded and a stacking layer solution of 1.25mL 0.5 M tris-
HCl/0.4% SDS pH 6.8 (National Diagnostics), 0.65mL 30% acrylamide/0.8% bis-
acrylamide, 3.05mL of sterilized distilled water, 25µL APS and 5µL TEMED was 
mixed and pipetted into the gel cast on top of the resolving layer. A 10 or 15 well 
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gel comb was then placed in the stacking layer with care to prevent any bubble 
formation in the wells. The gel was allowed to incubate at room temperature for 
30 minutes to allow the stacking layer to polymerize. The gel was removed from 
casting apparatus and wrapped in a wet paper towel, then in plastic wrap and 
stored at 4°C. 
 
Western Blot 
 Cultured cells were analyzed for NRP2 expression via western blot. Cell 
lysate samples were diluted with distilled water to allow loading of 40µg of protein 
per well. 5µL 6X-reducing SDS Sample Buffer was added to all samples, 
including Precision Plus Protein Standard #161-0374 (Bio-Rad). All samples and 
ladder were boiled for 5 minutes and spun down. The SDS-Page gels were 
immersed in 1X running buffer (Bio-Rad). All wells of the gel were flushed with 
1X running buffer to remove salt deposits. 30µL of each prepared sample and 
ladder was added to each well. The lid was placed on the running apparatus and 
connected to the power supply. Gels were typically run for 2 hours at 90V. After 
completion of the run, the gel mold was removed from the apparatus and 
separated, freeing the gel. The protein samples were then transferred to 
nitrocellulose membrane (Bio-Rad) by running for 2 hours at 300mA in 1X 
transfer buffer (Boston Bioproducts). Upon completion, ladder positions were 
marked on the membrane. The membrane was then blocked by incubating the 
membrane in 3% milk (3g dry non-fat mile blotting grade blocker (Bio-Rad) in 1X 
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Tris Buffered Saline (TBS)) for 30 minutes. The membrane was then washed 
three times in TBS-T (1% Tween 20 (Sigma), 1X TBS) for 10 minutes per wash 
with agitation. The membrane was incubated with rabbit anti-nrp2 monoclonal 
antibody (Cell Signaling Technologies) at 1:1000 concentration in TBS-T for 2 
hours at room temperature with agitation. The primary antibody solution was then 
poured off the membrane and saved for later use. The membrane was then 
washed in TBS-T as previously described, three times for 10 minutes each with 
agitation. Secondary antibody solution was the prepared with HRP-conjugated 
anti-rabbit antibody (GE Healthcare UK. Secondary antibody solution was 
pipetted onto the membrane and incubated for 1 hour with agitation. The 
membranes were washed in TBS-T a final three times for 10 minutes each with 
agitation. A 1:1 solution of Oxidizing reagent and Enhanced Luminol Reagent 
prepared from a Western Lighting Plus-ECL kit (Perkin Elmer). The membrane 
was incubated in this solution for 5 minutes before exposure. 
 
 
In vivo 
 
Mouse Genotyping 
 Three separate lines of mice were maintained, two C57BL/6 “black 6” lines 
and one NU/J “nude” line (Jackson Laboratories). The primary line maintained 
was a neuropilin2 knock-out green fluorescing protein (GFP) knock-in black 6 
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mouse line. To genotype, the mice were anesthetized and a portion of the ear 
removed. The ear was examined via fluorescence microscopy. Presence of the 
knockout allele was determined by noting GFP fluorescence in the hair follicle. If 
GFP fluorescence was present, the ear was analyzed using Transnetyx mail-
order genotyping service. This service probed the sample for the presence of a 
wild-type neuropilin2 gene with presence indicating a heterozygote and absence 
indicating a knockout. The second black 6 line contained a Cre gene under 
control of a Lyve-1 promoter, producing a tissue specific knockout upon breeding 
with a loxP-NRP2 mouse (floxed NRP2) obtained from another lab. These mice 
were genotyped using Transnetyx with a two-probe system. Samples were 
probed for the presence of the Cre gene, and then probed for a wild-type Lyve 
gene. Outcomes of this analysis are seen in (Figure 10).  
 
 
 
 
 
 
 
 
 
 
Figure 10 │ Genotyping Report: a sample genotyping report from 
Transnetyx. Genotype is indicated by corresponding colored text. In red, 
the heterozygote possesses both the Cre gene and the wild-type Lyve-1 
promoter. In yellow the homozygote posseses the Cre gene but lacks 
the wild-type Lyve-1 promoter. In blue, the wild-type mouse does not 
possess the Cre gene, but does have the wild-type Lyve-1 promoter. 
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Delayed-Type Hypersensitivity Assay 
 Ear swelling was examined in wild type and NRP2 knockout mice by 
inducing a delayed-type hypersensitivity reaction with 4-ethoxymethylene-2-
phenyl-oxazolin-5-one (oxazolin)(Aldrich). A 2% oxazolin solution was made in 
1:4 olive oil:acetone. To prime the immunologic response, mice were 
anesthetized and 50µL 2% oxazolin was pipetted onto the ventral abdomen 
along with 5µL per paw. Mice were left for 5 days to allow their allergic response 
to oxazolin to develop. After 5 days an initial baseline ear thickness 
measurement was taken with a No. 7326 caliper (Mitutoyo) and the allergic 
response was induced by pipetting 10µL 1% oxazolin to each side of the ear to 
be measured. Measurements were taken every 24 hours thereafter for up to 11 
days. Ears were removed from mice on days 1, 4 and 7 for histological analysis. 
The thickness difference was calculated for each mouse and graphed in Excel. 
 
Tumor Growth Assay 
 B16F10 melanoma cells overexpressing VEGFC were obtained originally 
from the Jain laboratory (Isaka et al., 2004) and cultured (Table 1) until plates 
were visually confluent. Plates were trypsinized and the cells counted using a 
hemocytometer to give an estimate of cell number needing approximately 1.3 x 
10^6 cells per mouse. The cells were spun down and resuspended in enough 
Hank’s Buffered Salt Solution (HBSS) to yield 1.1x10^6 cells per 100µL. Mice 
 40 
were anesthetized and injected subcutaneously with 100µL of cell solution. Mice 
were monitored every 48 hours after injection and measurements of length and 
width of the tumor were taken with a mechanical caliper once the tumors were 
detectable. Mice were sacrificed when the average of the length and the width 
exceeded 10mm. The tumor volume was estimated using the formula 
length*width2*0.52 and graphed in Excel. Tumors were removed from mice and 
preserved for histological analysis. 
 
 
Immunohistochemistry 
 
Fixation 
 Ears from the DTH assay and tumors from the tumor growth assay were 
fixed in paraffin or frozen section. Paraffin fixed tissue samples were left in 
formalin overnight, and then placed in Phosphate Buffered Solution (PBS) for 
histological preparation. Frozen section tissue samples were snap frozen in OCT 
using liquid nitrogen. 
 
Immunostaining 
 Paraffin section slides were de-paraffinized with xylene and re-hydrated to 
PBS through an ethanol ladder. Antigen retrieval was performed with Proteinase 
K at 20µg/mL (Roche) at 37°C for 15 minutes. A hydrophobic ring was drawn 
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around the tissue sample using a marker pen. The slides were washed in PBS 
three times for 3 minutes per wash. Endogenous peroxidases were blocked with 
3% hydrogen peroxide (Sigma) in methanol for 12 minutes at room temperature. 
The slides were washed in PBS three times for 3 minutes per wash. The slides 
were blocked with Tris-NaCl-blocking buffer (TNB) for 1 hour at room 
temperature. Primary antibody was prepared at appropriate concentration in TNB 
(Table 2). 250µL primary antibody solution was added per slide. Slides were 
incubated overnight at 4°C. The slides were washed three times for 3 minutes 
per wash. Secondary antibody solution was prepared at the appropriate 
concentration in TNB (Table 2). 250µL secondary antibody solution was added to 
each slide and allowed to incubate for 1 hour at room temperature. During this 
time the corresponding Vectastain Avidin/Biotinylated Enzyme Complex (ABC) kit 
(Vector Labs) was prepared. The slides were washed three times for 3 minutes 
per wash. The ABC kit was pipetted onto the slides and left to incubate for 30 
minutes at room temperature. The slides were washed as before. The DAB 
Peroxidase Substrate or Red Alkaline Phosphatase Substrate kits (Vector Labs) 
were then added to each slide and observed for stain development (TABLE 2). 
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Antigen Marker 1° Ab 
1° 
Conc. 
2° Ab 
2° 
Conc. 
Vectastain 
ABC kit 
Substrate Kit 
CD-31 
Pan-vessel 
marker 
Anti-mouse CD-
31 (Cell 
Signaling 
Technologies 
#3568) 
1:200 
Biotinylated 
anti-syrian 
hamster 
1:200 
Elite 
(Vector 
Labs pk-
6200) 
DAB kit 
(Vector Labs 
SK-4100) 
Lyve-1 
lymphatic 
marker 
Anti-
mouse LYVE-
1 (ReliaTech 10
2-PA50) 
1:80 
Biotinylated 
anti-rabbit 
1:200 
Standard 
(Vector 
Labs ak-
5000) 
Red AP kit 
(SK-5100) 
Podo 
lymphatic 
marker 
Anti-
mouse Podo 
(Relia-Tech 
103-M40) 
1:100 
Biotinylated 
anti-rat 
1:200 
Standard 
(Vector 
Labs ak-
5000) 
Red AP kit 
(SK-5100) 
Table 2 │Immunohistochemical Staining: listed are the antigen, marker, 1° 
and 2° Ab concentrations, Vectastain ABC kit and Substrate kit for each 
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RESULTS 
 
NRP2 deficient mice show maintained ear swelling 
 
 Due to NRP2’s extensive expression in cutaneous lymphatic vessels, we 
hypothesized that NRP2 KO mice would maintain ear swelling in response to 
oxazalone-induced DTH reaction. 24 hours after induction, both wild-type (WT) 
and KO mice displayed swelling of more than 300µm, although the KOs did not 
swell to as great a degree as our wild-type mice (Figure 11a). After 72 hours, the 
KO mice showed a greater degree of swelling than their WT littermates, which 
persisted until the ears were taken on day 7 for histological analysis (Figure 11a). 
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Figure 11a │ DTH Assay:  NRP2 KO mice (Red triangle, red line) show 
prolonged ear swelling in comparison to WT littermates (blue diamond, blue 
line). Ear swelling is expressed as difference in µm of the ear. 
 45 
 
Previously, this experiment was conducted by Nick Levonyak from the lab 
(Figure 11b). During that experiment, KO and WT littermates showed the same 
degree of swelling. From day 2 onward, the KO mice showed significantly 
increased swelling over the WTs, which persisted to the end of the 11 day trial. 
The KO mice were monitored thereafter, finding that swelling was still persistent 
at 21 days. 
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Figure 11b │DTH Assay: Nrp2 KO mice (Red triangle, red line) show prolonged 
ear swelling in comparsion to WT littermates (blue diamond, blue line). Ear 
swelling is expressed as difference in µm of the ear. 
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 Histological analysis was performed on WT ears taken at days 1, 4 and 7, 
and on KO ears taken at day 1 and 7. Marked swelling can be seen in both WT 
and KO ear sections from day 1 (Figure 12). Previous experiments by Nick 
Levonyak have shown the characteristic prolonged swelling in histological 
sections of KO ears and a return to normal in WT ears. Ears were stained for the 
pan-vessel marker CD-31 and lymphatic marker Lyve-1. Preliminary examination 
of CD-31 stained ears did not reveal obvious differences between the WT and 
KO at any day 1 or day 7. The mean vessel diameter and vessel density should 
be analyzed via software to confirm this. Lyve-1 staining revealed drastic dilation 
of lymphatics on day 1 in both the WT and the KO (Figure 11). We hypothesize 
that the prolonged swelling found in NRP2 KOs is due to maintained dilation of 
large lymphatic vessels. Comparison of Lyve-1 staining on day 7 indicates that 
the lymphatic vessels of NRP2 KO mice may remain dilated beyond those of 
their WT counterparts. Again, quantitative analysis via software is necessary to 
make a firm conclusion in this regard.  
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B16F10 Melanoma expresses NRP2 
 Expression of NRP2 was verified via western blot in three candidate 
B16F10 melanoma cell lines for our tumor growth assay. Two of these cell lines 
were transfected to over-express VEGFC while the third was a normal B16F10 
melanoma line. All three were confirmed to express NRP2 (Figure 13). 
WT 
NRP2 KO 
Day 1 Day 7 
Figure 12 │ Histology of DTH ear swelling in NRP2 KO and WT mice: Ear 
sections of WT (top) and KO (bottom) mice (10X). Sections were stained with 
Lyve-1, a lymphatic marker (red), then counter-stained hematoxylin (faint blue-
grey). 
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NRP2 deficient mice have smaller tumors with smaller blood vessels 
In our tumor growth assay, we injected one million B16F10-VEGFC cells, 
which over-express VEGFC and were shown to express NRP2 in the western 
blot shown above. We hypothesized, based on previous studies by Nick 
Levonyak, that the tumors would be smaller in the NRP2 KO mice. This was 
confirmed by the tumor growth assay, which showed that NRP2 KO mice have 
significantly smaller tumors that their WT littermates from day 9 after injection 
onwards (Figure 14). We believe that the tumors in the KO mice remain dormant 
and are not capable of triggering the angiogenic switch. 
  
Figure 13 │ B16F10 Melanoma expresses NRP2: NRP2 protein levels 
were verified by a band at ~130kDa. Loading equivalence was checked 
via GAPDH protein levels, seen in bands at ~37kDa. Brain lysate was 
used as a positive control, while heart lysate was used as a negative 
control for NRP2 protein presence. 
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WT mice were sacrificed at day 17 after injection due to tumor burden and 
tumors were resected for histological preparation. Tumors from the KO mice 
were surgically removed and prepared for histology in the same manner. Tumor 
sections were stained for the pan-vessel marker CD-31 and the lymphatic marker 
Lyve-1. We hypothesized that tumors from NRP2 KO mice would display a 
reduced mean vessel diameter and vessel density. In addition, we expected to 
see increased intratumoral lymphatics. Tumors grown in NRP2 KO mice showed 
smaller vessels than their WT counterparts (Figure 15). However, vessel density 
did not appear to be affected. Both diameter and density should be quantified via 
software to confirm this. Intratumoral lymphatics did not appear to increase, 
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Figure 14 │NRP2 KO mice have smaller tumors: NRP2 KO mice 
(red triangle, red line) display significantly reduced tumor growth from 
their WT littermates (blue square, blue line). * indicates P<.01. 
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although they should be counted via software to confirm this finding. In addition, 
peritumoral lymphatics should also be quantified in the same manner. 
 
 
 
 
 
 
 
 
 
 
 
 
  
KO WT 
Figure 15 │ NRP2 KO mice have smaller vessel lumens: Tumors 
were removed from KO (left) and WT (right) mice and placed in frozen 
section. Sections were stained for CD-31 (brown). Images were taken 
within the tumor. 
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DISCUSSION 
 
 Our increasing knowledge of the diversity of NRP2 expression and 
function demands deeper exploration. In the DTH assay, we propose that the 
prolonged swelling in NRP2 KO ears is due to maintained dilation of large 
lymphatic vessels. These vessels may remain dilated due to the mutant mouse’s 
inability to initiate lymphangiogenesis through NRP2 signaling. In the future, we 
will confirm that angiogenesis/ lymphangiogenesis are occurring by staining for 
the proliferation marker Ki-67. Without smaller lymphatic vessels which arise 
through lymphangiogenesis, the remaining larger lymphatics are the only route 
for fluid to drain from the interstitium. We propose that these large lymphatics 
remain so dilated that they are not functional, possibly because the lymphatic 
valves are so far apart that they cannot prevent backflow. Investigating the 
functionality of lymphatic vessels has proven difficult for the lab, due to the 
difficulty in injecting dye into a mouse ear that is typically ~500µm thick. In 
addition, our black mice make it difficult to see dark colored dyes in the ear, 
further confounding our efforts, although in the future we intend to attempt this 
technique with radio-labelled dyes. Recently, it was shown that the SEMA3A-
NRP1-Plexin signaling axis is essential in lymphatic valve formation (Bouvree et 
al., 2012). It is plausible that NRP2 may also play a role in this process due to its 
high expression on lymphatic vessels. Differences in the KO and Wild-type 
vasculature must also be considered. It is possible that the blood vessels in the 
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KO are leakier, thus resulting in a net leakage of fluid into the interstitium even if 
the KO maintains normal lymphatic functionality 
 Angiogenesis/ lymphangiogenesis do not represent the only possible 
explanations for the prolonged swelling seen in NRP2 KO ears. Because NRP2 
is also expressed on cells of the immune system, there may be an as yet 
undefined role for NRP2 in the migration of these cells to the site of inflammation. 
This is another area that has been explored in NRP1 studies, where it was 
shown that NRP1 mediates T-cell migration to tumor sites in a VEGF-dependent 
manner (Hansen, 2013). It is plausible that NRP2 deficient mice are not capable 
of bringing in leukocytes to resolve the cause of their inflammation, which could 
lead to the prolonged inflammation we observed. To address this, we propose 
the use of tissue specific knockouts to observe the specific roles NRP2 plays in 
cells that express it. Our lab plans to repeat the DTH experiment using a 
lymphatic-specific NRP2 KO to examine the role NRP2 plays in physiologic 
inflammation without also implicating NRP2 functions elsewhere in the organism. 
The data from such a study will be especially insightful when compared with a 
leukocyte-specific NRP2 KO currently being developed by a collaborating lab. 
Finally, a tamoxifen-induced NRP2 KO mouse would allow us to address any 
difference that occurs during the development of the mouse vasculature due to 
NRP2 being knocked out because Nrp2 would only be knocked out during the 
experiment in this model, not during development of the vasculature. Taken 
together, the data we present here regarding physiological angiogenesis and 
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lymphangiogenesis open up more questions than they answer, but further study 
of this phenomenon using the DTH assay promises to deepen our understanding 
of NRP2’s function. 
 
 The drastically reduced tumor growth seen in the NRP2 KO mice in our 
B16F10-VEGFC tumor growth assay gives great precedent to the possibility of 
an antiangiogenic therapy being highly effective. This result is given even greater 
weight when considered alongside the previous work of Nick Levonyak in our lab, 
which showed smaller, less metastatic pancreatic cancer tumors in NRP2 KO 
mice. Examination of the CD-31 staining reveals that the vessels in the KO 
tumors are much smaller in diameter, although they appear to be equally 
numerous as in their WT counterparts. We believe the reduction in tumor growth 
seen in the NRP2 KO is due to this inhibition of effective angiogenesis, depriving 
the hungry tumor cells of nutrients and oxygen. Work by Matt Migliozzi in our lab 
has shown that SEMA3F treatment can be effective at preventing tumor growth 
and metastasis in nude mice with A375SM human tumors, which are also NRP2 
positive. In the future, we would like to repeat this tumor growth assay with 
B16F10 melanoma in WT mice and apply a SEMA3F treatment, which we 
believe will be highly effective at reducing both tumor growth and metastasis.  
Thus, in our KO model, anti-NRP2 therapy is only simulated in the host, 
since the tumor can still respond to any NRP2 signaling produced within the 
tumor microenvironment or produced by the host. In a clinical setting however, 
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this would not be the case, as both patient and tumor (depending on which tumor 
type) would be NRP2 positive and able to respond to anti-NRP2/ antiangiogenic 
signaling. We expect this would greatly increase the antitumor effects seen here 
not only because of SEMA3F’s antiangiogenic signaling mediated through the 
NRP2-Plexin pathway, but also due to its inhibition of VEGF-VEGFR binding. In 
the future, we would like to repeat this experiment with a NRP2-negative tumor in 
NRP2 KO mice, where we would expect no difference from the WT, due to lack 
of NRP2-axis signaling from the tumor. In addition, B16F10 melanoma is highly 
aggressive, so much so that the mice are typically sacrificed in ~2.5 weeks due 
to tumor burden. By repeating this experiment with a slower growing tumor, we 
would be able to determine if the reduction in growth is maintained or if the tumor 
is capable of surmounting the lack of host NRP2 by signaling through other 
pathways. Repeating this experiment with a tumor which expresses Nrp2 on the 
tumor cells but not the vasculature, such as T241, we would expect to see no 
difference between WT and our KO. 
 In one of his final reviews, Dr. Judah Folkman stated his belief that within 
the next decades, antiangiogenic and angiogenic therapies would revolutionize 
medicine and bring relief to millions suffering worldwide from a myriad of 
diseases. The data presented here show that we are approaching this time, 
especially in regard to antitumor agents such as SEMA3F, but the data also 
show that for every door we close, two more open. As always, further study is 
required to deepen our understanding of angiogenesis, which appears to become 
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more complicated to more it is investigated. One aspect that has not changed 
however, is the promise held within control over this powerful biological 
phenomenon 
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